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Abstract
Background: Disseminated intravascular coagulation (DIC) is a very rare complication of disseminated
cytomegalovirus (CMV) infection. So far it is mainly described for immunocompromised patients.
Case presentation: A 49-year-old immunocompetent Caucasian male presented with sudden onset of fever and DIC
due to primary CMV infection, which was treated with Valganciclovir. CMV-specific IgG-avidity and epithelial cell-
specific neutralisation-capacity developed five weeks after onset of symptoms. We describe the first case of an
immunocompetent patient suffering from DIC due to a CMV primary infection successfully treated with Valganciclovir.
Conclusions: Primary CMV infection can occur accompanied with life threatening complications even in
immunocompetent patients. Immediate treatment with Valganciclovir should be considered as an early treatment of
choice in severe cases since specific neutralisation capacity might need several weeks to develop.
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Background
CMV infection is usually a threat in the haematological
or transplant setting [1], since most of the patients with
severe infections are immunocompromised, or during
pregnancy or lactation in the context of congenital or
postnatal CMV infection. Disseminated intravascular
coagulation (DIC) due to CMV is reported more
often in immunocompromised patients with severe
CMV infections [2, 3], whereas in immunocompetent
patients primary CMV infection is most frequently
clinically silent [4]. So far there are only two pub-
lished cases that suggest DIC due to CMV primary
infection in immunocompetent patients [5, 6]. Here,
we demonstrate for the first time the emergence of
severe CMV primary infection-associated DIC. The
diagnosis of CMV primary infection was established
by detection of a high CMV IgM index and a low
CMV IgG level without recgB1/2-IgG reactivity, and
later confirmed by an increase in CMV IgG avidity
maturation and epithelial cell-specific neutralisation
capacity five weeks after the acute onset of fever epi-
sodes. The acute clinical manifestation, however,
could apparently be controlled by initial short-term
antiviral therapy with valganciclovir (VGCV).
Case presentation
A 49-year-old Caucasian male appeared at the emer-
gency room with fever, up to 40 °C, chills and dyspnea
for one week. His medical record included hypertension,
sleep apnoea, and hydronephrosis of the right kidney
due to a former nephrolithiasis. He worked as a taxi
driver and strongly denied any substance abuse. He nei-
ther reported any regular medication nor any signs of
immunodeficiency in the past.
Upon admission the patient presented with blood
pressure of 140/80 mmHg, heart rate of 113/min, body
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temperature of 39.2 °C, and a respiratory rate of 24/min.
Physical examination yielded normal results. Initial
blood tests revealed a normal white blood cell count
(WBC) of 5.1 × 109/l (4–9.5), an internationalised ratio
(INR) of 1.5, an activated partial thromboplastin time
(aPTT) of 42 s (<40 s), D-dimers of 15 μg/ml (0–0.23), a
CRP of 21.02 mg/dl (<0.5), a procalcitonin level of
1.35 ng/ml (<0.1), and a lactate dehydrogenase activity
of 823 U/l (<250). Liver and kidney function tests were
within normal range. Abdominal ultrasound examin-
ation as well as chest X-ray images did not show abnor-
malities besides the known hydronephrosis. To look for
a source of infection and to exclude thrombosis or pul-
monary embolism, we performed a whole body CT-scan
with contrast agent, but without gain of information.
We started an empirical antibiotic treatment with piper-
acillin and tazobactam. However, fevers kept spiking
within the following 24 h and the patient developed
leukocytopenia (3.6 × 109/l) and thrombocytopenia
(66 × 109/l, 150–450). Repeated blood cultures were
negative but despite normal urine analysis, urine cul-
ture was positive for Enterococcus faecium (less than
10,000 CFU). Thus, diagnosis of urosepsis with DIC
was most likely and antibiotic treatment was broad-
ened to meropenem and vancomycin to include com-
mon resistant bacteria.
Despite broad antibiotic therapy, in the following 24 h
D-dimers and CRP increased and fevers were still on-
going. WBC and thrombocytes decreased further (Fig. 1).
Given the clinical course of the disease with progressive
leukocytopenia and thrombocytopenia, we suspected a
viral infection and performed serological screening for
tick-borne encephalitis, HHV-6, HIV, HBV, HCV, EBV,
Parvovirus B-19, HSV-1/2, and CMV. While most sero-
logical tests were negative or only showed signs of past
infection (for EBV and HSV-1/2), CMV-testing revealed
an early primary CMV infection, characterised by a low
IgG concentration and a high IgM index (>5.0) along
with low IgG avidity (ECLIA, Roche) (Table 1). Dissemi-
nated CMV infection was confirmed by a positive PCR
for CMV DNA in leucocytes and plasma. We therefore
started valganciclovir treatment, with oral administration
of 900 mg doses twice a day, due to the patient’s severe
clinical conditions, in particular the worsened coagulop-
athy (Fig. 1). After administration of four valganciclovir



































































Fig. 1 Monitoring of relevant blood tests in the course of infection. The arrow indicates the duration of valganciclovir therapy. Both diagrams
show a return to normalcy of all parameters after brief antiviral therapy
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Table 1 Synopsis of CMV recombinant IgG epitope-specific avidity maturation (Mikrogen, Germany), CMV IgG increase, and decrease of IgM indices (ECLIA, Roche) in context of
PCR results and viral shedding. In week 5, nested PCR was positive while real time PCR was negative, corresponding to viral copy numbers/ml plasma in the range of 200–600
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and thrombocyte counts increased, and fever and chills
disappeared (Fig. 1). We therefore stopped treatment
with Valganciclovir after four doses. Further serological
testing after four days of initiating antiviral therapy
revealed still low avidity IgG antibodies to CMV;
CMV-PCR was negative in leukocytes and plasma.
A follow-up in our outpatient clinic after one
month showed the progress of CMV primary infec-
tion with an increase of CMV-specific IgG, avidity
maturation and a decrease of IgM indices. CMV-DNA
could be detected in plasma by nested PCR (LOD:
200 copies/ml) but not by quantitative real time PCR
(LOD: 600 copies/ml). Therefore, the viral load
ranged between 200 and 600 copies/ml of plasma.
Viral shedding was observed in urine samples
(Table 1) and throat swabs. About five weeks after
the initial admission, the CMV specific antibodies had
increased ten-fold, the avidity index had slowly in-
creased to 35 %, which still represents low avidity,
and IgM index had dropped from 3.2 to 1.4. Viral
shedding could be documented with a viral isolate
from urine microculture. Anti-CMV-gB2-IgG reactiv-
ity was not detectable, whereas gB1 reactivity was
already weakly detectable (Table 1). The patient had
no clinical symptoms of ongoing infection. Blood
count, CRP, and clotting analysis were normal and he
had resumed work.
In blood tests performed at a one year follow-up in
our outpatient clinic, we could not detect anti-CMV-
IgM antibodies, but we did detect high avidity IgG anti-
bodies and results from plasma CMV-PCR were negative
(Table 1). Blood count and clotting analysis had no
pathological findings.
The follow-up tests performed show the typical dy-
namics of a primary CMV infection with a loss of p150
rec IgM reactivity (IgM index <1,0), a steep increase in
CMV IgG (about 4-fold), and the emergence of gB2-IgG,
which indicates CMV neutralising antibodies (Table 1,
Fig. 2, Additional file 1). Interestingly, the CMV specific
antibody pattern had already been present with high ti-
ters at the very onset of symptoms, while gB1 and gB2
reactivity only developed slowly (Fig. 2, Additional
file 1). These findings support the initial diagnosis of
an acute onset of a primary CMV infection.
Retrospectively performed longitudinal epithelial cell-
specific neutralisation experiments revealed the emer-
gence of neutralising antibodies about five weeks after
onset of clinical symptoms. This emergence is accom-
panied by a steep increase of CMV avidity maturation.
However, the neutralising capacity was not fully devel-
oped five weeks after onset of symptomatic infection
(Fig. 2).
Details of the methodology can be found in Additional
file 1 “Methods”.
Conclusions
CMV is able to infect many different cells in various tis-
sues in the human body. Several CMV in vitro assays
have proven thrombogenic potential and a procoagulant
phenotype of endothelial cells [7]. In rat models, CMV
infection has led to haemorrhage, thrombosis, and ab-
normal coagulation blood tests due to infection of
Fig. 2 Epithelial cell-specific (ARPE-19) plaque reduction neutralisation capacity of the sera 1–4. Reference sera include a negative pool
(N = 100 sera from seronegative women at birth), and a pool of latently CMV-infected women at birth (IgG positive, IgM negative, high
IgG avidity) as well as the hyperimmunoglobulin preparation Cytotect (Biotest, Germany) [11]. The shaded columns show the mean
number (N = 3 replica) of CMV IE1-stained plaques (NIEA plaques) in the absence of CMV-specific antibodies after 5 days of incubation.
Black columns show the percentage of neutralisation via plaque reduction of each serum panel. Gray columns show CMV IgG avidity
(AI ECLIA, %). Specific NT capacity is not present in early sera of the patient (within one week of admission). However, after 5 weeks,
NT50 values are reached
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endothelial cells comparable to DIC [8]. A recent report
also suggests that CMV activates and interacts with a
subset of human platelets without immediate thrombotic
events but with enhanced inflammation due to neutro-
phil extravasation and formation of platelet-leukocyte
aggregates [9]. In contrast, thrombosis in both arterial
and venous circulation, detected via anti-cardiolipin-and
anti-ß (2) glycoprotein I- antibodies, has been described
in an immunocompetent patient with primary CMV in-
fection [10].
DIC appears to be a very rare complication of dissemi-
nated CMV infection in general. It has been described
rarely for immunosuppressed patients [2, 3], and only
twice for immunocompetent patients [5, 6]. The first pa-
tient, reported in 1972, died of severe CMV cardiomyop-
athy and DIC after being treated with heparin and
digoxin [6]. The second patient, reported in 2006, sur-
vived severe DIC due to plasma exchange treatment [5].
Treatment with ganciclovir or valganciclovir was not
conducted in the second patient. To the best of our
knowledge, the case presented here is the first case in
which an immunocompetent patient with disseminated
intravascular coagulation was treated with short-term
valganciclovir administration with longitudinal analysis
of CMV IgG avidity maturation and epithelial cell-
directed neutralisation during CMV primary infection.
Treatment of CMV infections in immunosuppressed
patients regularly includes the reduction of immunosup-
pressants, and/or treatment with antiviral drugs such as
ganciclovir or valganciclovir [1]. In immunocompetent
patients, however, a primary CMV infection is mostly
self-limiting. Besides treating the underlying cause of
DIC, DIC is usually treated with antifibrinolytic drugs
such as cyclocapronic acid, supplementation of clotting
agents, or plasma and low dose heparin.
In our patient, the primary CMV infection was
diagnosed after excluding other possible diagnoses (e.g.,
negative blood cultures, no improvement after broad
antibiotic treatment) and by detection of CMV-specific
IgM reactivity in the context of low IgG avidity and low
IgG levels in the absence of anti-CMV recgB2 IgG with
broad epitope specific IgM reactivity against CMV IE1,
p150, CM2, and p65 [11]. Fibroblast-specific neutralising
antibodies usually become detectable after 4–5 months
during primary infection. In contrast, the epithelial cell–
specific neutralisation already emerges within five weeks
of the onset of clinical symptoms. Therefore, immune
control can be achieved about five weeks after the onset
of symptoms.
We decided to start the treatment with valganciclovir
as an attempt to stop the ongoing fever spikes and the
progressive coagulopathy and aiming to avoid plasma-
pheresis. According to other reports of immunocompe-
tent patients suffering from CMV infection of other
organs (e.g., lung or bowel), treatment with only a few
doses of valganciclovir influenced the course of disease
positively [12–15], and indeed, our patient improved
rapidly within 24 h. Therefore, plasmapheresis and fur-
ther treatment of DIC could be avoided. We suggest that
inhibition of CMV proliferation with targeted antiviral
treatment reduced the viral load significantly and
stopped the progression of endothelial inflammation and
therefore terminated the DIC. Thus, only immediate
therapy with valganciclovir could successfully bridge the
gap between the onset of symptoms and immune
control.
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